Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 15 to 23 amino acid residues in defined sequence
Reexamination Certificate
2006-12-26
2006-12-26
Chan, Christina (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
15 to 23 amino acid residues in defined sequence
C530S350000, C530S387300, C530S866000
Reexamination Certificate
active
07153932
ABSTRACT:
The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.
REFERENCES:
patent: 5101025 (1992-03-01), Piatak, Jr. et al.
patent: 5376546 (1994-12-01), Bernhard
patent: 5416202 (1995-05-01), Bernhard
patent: 5621083 (1997-04-01), Better et al.
patent: 5624827 (1997-04-01), Rosenblum et al.
patent: 5744580 (1998-04-01), Better et al.
patent: 5837491 (1998-11-01), Better et al.
patent: 6146850 (2000-11-01), Better et al.
patent: RE37462 (2001-12-01), Rosenblum et al.
patent: 6376217 (2002-04-01), Better et al.
patent: 6649742 (2003-11-01), Better et al.
patent: 2002/0168370 (2002-11-01), McDonald et al.
patent: 0 439 954 (1991-08-01), None
patent: WO 93/09130 (1993-05-01), None
Colombatti et al., “Selective killing of target cells by antibody-ricin a chain or antibody-gelonin hybrid molecules: comparison of cytotoxic potency and use in immunoselection procedures,”J of Immunology, 131:3091-3095, 1983.
Declaration of Michael G. Rosenblum, Ph.D.
U.S. Appl. No. 07/787,567, filed Nov. 4, 1991, Better.
Gekeler et al., “Mdr1/P-glycoprotein gene segments analyzed from various human leukemic cell lines exhibiting different multidrug resistance profiles,”Biochem Biophys Res Commun, 15:796-802, 1990.
Hertler et al., “Immunotoxins: A clinical review of their use in the treatment of malignancies,”J of Clinical Oncology, 17:1932-1942, 1989.
Lindbladh et al., “Characterization of a recominant bifunctional enzyme, galactose dehydrogenase/bacterial luciferase, displaying an improved bioluminescence ina three-enzyme system,”Eur. J. Biochem, 204:241-247, 1992.
Lindbladh et al., “Standard Calibration proteins for western blotting obtained by genetically prepared protein a conjugates,”Analytical Biochemistry, 197:187-190, 1991.
Lindbladh et al., “The design of a simple competitive elisa using human proinsulin-akaline phosphatase conjugates prepared by gene fusion,”Biochemical and Biophysical Research Communications, 149, 607-614, 1987.
Lindbladh et al., “Use of genetically prepared enzyme conjugates in enzyme immunoassay,” TIBS, 18:279-283, 1993.
Maclachlan et al., “Binding of a calcium sensitizer, bepridil, to cardiac troponin C,”J of Biological Chemistry, 265:9764-9770, 1990.
O'Hare et al., “Cytotoxicity of a recombinant ricin-A-Chain Fusion protein Containing a proteolytically-cleavable spacer sequence,”FEBS LETTt273:200-204, 1990.
Ready et al., “Ricin-like plant toxins are evoluntionarily related to single-chain ribosome-inhibiting proteins from phytolacca,”J of Biological Chemistry, 259:15252-15256, 1984.
Sharma et al, “Metal affinity chromatography or recombinant HIV-1 reverse transcriptase containing a human renin cleavable metal binding domain,”Biotechnol App Biochem, 14:69-81, 1991.
Sivam et al., “Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other a chain conjugates,”Cancer Research, 47:3169-3173, 1987.
Stirpe et al., “Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells,”J. of Biological Chemistry, 255:6947-6953, 1980.
Wiels et al., “38.13 a monoclonal antibody directed against a burkitt's lymphoma-associated antigen and its use as carrier for toxins,” 457-464.
Witt et al., “A new protein conjugate that replaces the use of secondary antibodies engineered from the two staphylococcal enzymes protein A and 6-phospho-β-galactosidase,”Protein Engineering, 5:267-271, 1992.
Yeh et al., “Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate,”PNAS USA, 89:1904-1908, 1992.
Better Marc D.
Carroll Stephen F.
Studnicka Gary M.
Chan Christina
Fulbright & Jaworski LLP
Huynh Phoung
Research Development Foundation
LandOfFree
Immunotoxins comprising ribosome-inactivating proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotoxins comprising ribosome-inactivating proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotoxins comprising ribosome-inactivating proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3694256